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Abstract
Background: Henoch-Schönlein Purpura (HSP) is the most common vasculitis of childhood and affects the small
blood vessels. Pulmonary involvement is a rare complication of HSP and diffuse alveolar hemorrhage (DAH) is the
most frequent clinical presentation. Little is known about the real incidence of lung involvement during HSP in the
pediatric age and about its diagnosis, management and outcome.
Methods: In order to discuss the main clinical findings and the diagnosis and management of lung involvement in
children with HSP, we performed a review of the literature of the last 40 years.
Results: We identified 23 pediatric cases of HSP with lung involvement. DAH was the most frequent clinical
presentation of the disease. Although it can be identified by chest x-ray (CXR), bronchoalveolar lavage (BAL) is the
gold standard for diagnosis. Pulse methylprednisolone is the first-line of therapy in children with DAH. An
immunosuppressive regimen consisting of cyclophosphamide or azathioprine plus corticosteroids is required when
respiratory failure occurs. Four of the twenty-three patients died, while 18 children had a resolution of the
pulmonary involvement.
Conclusions: DAH is a life-threatening complication of HSP. Prompt diagnosis and adequate treatment are
essential in order to achieve the best outcome.
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Background
Henoch–Schönlein purpura (HSP), also known as ana-
phylactoid purpura or, most recently, IgA Vasculitis
(IgAV), is the most common leukocytoclastic systemic
small-vessel vasculitis in childhood [1]. It is usually char-
acterised by non-thrombocytopenic purpura, with typical
purple, non-blanching papules, localised primarily on
the lower extremities and buttocks. It can also be associ-
ated with abdominal discomfort, joint symptoms such as
arthritis or arthralgia of large joints of the lower extrem-
ities, and risk of renal involvement [2].
The range of clinical manifestations of HSP is very
broad, varying from asymptomatic microscopic hematuria
to proteinuria and acute kidney injury (AKI) of various de-
grees up to rapidly progressive glomerulonephritis with
significant risk of chronic renal impairment [3]. Other
possible organ involvement includes cerebral vasculitis,
ureteral or bladder disease, and scrotal, penile or testicular
hemorrhage [4–6].
Piram et al., in a review published in 2013, estimated
the annual incidence of HSP in children to be between 3
and 26.7/100,000, demonstrating that it occurs two to 33
times more frequently in infants than in adults [7].
HSP is usually a self-limiting disease with an average
duration of 4 weeks; it can have a remitting-relapses
course especially within 3 months after initial resolution
and rarely, when complicated, it can be fatal [8].
Although the etiology remains unknown, a possible
link between genetic predisposition and environmental
factors are considered crucial for the pathogenesis of
HSP [9, 10].
The diagnosis of HSP is based on clinical findings.
The diagnostic criteria for HSP were recently revised by
various study groups (EULAR European League Against
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Rheumatism, PRINTO Pediatric Rheumatology Inter-
national Trials Organisation and PRES Pediatric
Rheumatology European Society), and are listed in
Table 1 [11, 12].
Pulmonary involvement in HSP is a rare but severe
complication and its presence increases the vasculitis
morbidity and mortality rates [13–16].
Lung involvement in children with HSP is extremely
rare. In particular, sub-clinical lung impairment without
respiratory symptoms assessed by pulmonary function
tests has been seen during the active phase of the dis-
ease, suggesting that the course of the disease involves a
malfunction of the alveolar-capillary membrane due to
the deposition of immune complexes containing IgA
within the vessels of the alveolar septa [17–19].
Chaussen et al. reported a decrease in lung transfer for
carbon monoxide (TLCO) in 28 out of 29 patients with
HSP without pulmonary symptoms, with normal lung
volumes and normal blood gas values, although mild
radiological signs of interstitial lung involvement were
observed in 18 of 26 patients. In all cases, the TLCO
values normalised after complete clinical recovery [20].
TLCO impairment is associated with granular immune
complex deposition, neutrophilic interstitial infiltration
(acute inflammation), fibrin deposition and consequent
fibrinoid necrosis, finally resulting in a thickening of the
capillary wall. Nuclear debris may be present in the in-
terstitium, representing leukocytoclasis [21, 22].
This hypothesis is supported by the results of autop-
sies on patients who died of diffuse alveolar hemorrhage
(DAH), which were characterised by pulmonary edema
with intra-alveolar hemorrhage, interstitial fibrosis, arter-
ial neutrophilic infiltrate, loss of nuclear staining in the
alveolar walls and septa, and capillary wall necrosis. The
immunochemistry examination shows granular depos-
ition of IgA along the alveolar septa, suggesting an im-
mune pathogenesis [23, 24].
The absence of IgA on the lung biopsy does not rule
out a potential role in the pathogenetic mechanism, due
to the rapidity of the immunofluorescence changes, for
example on the skin, where IgA disappears just a few
days after its deposition [25, 26].
Massive lung involvement such as DAH is rare, espe-
cially in the pediatric age. Patients with pulmonary
hemorrhage have kidney involvement in up to 95% of
cases, more than double the percentage of patients with
no pulmonary involvement, sign of the presence of a
more severe disease [27, 28].
The aim of this review is to provide a critical appraisal
of the medical literature regarding the lung involvement
in HSP in children.
Methods
A research of the literature was performed in PUBMED
database, using the terms “Henoch-Schönlein Purpura”,
“anaphylactoid purpura”, “Diffuse alveolar hemorrhage”,
“Pulmonary Involvement”, “Children”. Only those arti-
cles that were reported in English literature and included
pediatric patients (0–18 years) with a HSP and lung
involvement were included for this narrative review. We
found 23 cases between 1979 and 2019, and we de-
scribed symptoms, diagnostic findings, treatment and
outcomes.
Results
Between 1979 and 2019, there were 23 pediatric case-
reports of children with HSP who developed DAH. The
main findings of these case-reports are described in
Table 2.
The average age at the onset of HSP with pulmonary
involvement was 10.2 years, with little difference be-
tween males (12 cases) and females (11 cases).
Almost all children with pulmonary hemorrhage had
renal involvement, ranging from hematuria often associ-
ated with proteinuria, to nephritis or nephrotic protein-
uria through to AKI [8, 10, 14, 15, 25–27, 29–37, 39].
The co-occurrence of rapidly progressive glomerulo-
nephritis and DAH is also known as “pulmonary renal
syndrome” and it is primarily related to an autoimmune
etiology. However, Gd-IgA1 pathway is probably in-
volved, due to the presence of similar manifestation in
other IgA related disorders, such as IgA nephropathy
(IgAN), ANCA-associated vasculitis overlap syndrome,
IgA-dominant post-infectious glomerulonephritis, IgA-
variant Goodpasture’s syndrome and IgA-producing
monoclonal gammopathy [40–42].
Twelve of twenty-three children were screened for
ANCA: 11 were negative and one was c-ANCA nega-
tive but p-ANCA positive (this patient had IgA depos-
ition in kidney biopsy but the possibility of concurrent
ANCA-associated vasculitis could not be excluded at
all). Eleven of twenty-three children were not screened
for ANCA: six of them did not perform kidney biopsy,
three had IgA deposition in renal biopsy, two had other
glomerular pattern with different deposits in biopsy. Al-
most all children had a normal complement screening
Table 1 EULAR/PRINTO/PRES diagnostic criteria of Henoch-
Schönlein Purpura
Palpable non-thrombocytopenic purpura (mandatory criterion) with
lower limb predominance in the presence of at least one of the follow-
ing four features:
- Abdominal pain
- Histopathology showing typical leukocytoclastic vasculitis with
predominant IgA deposition or proliferative glomerulonephritis with
predominant IgA deposition
- Arthritis (acute, any joint) or arthralgia
- Renal involvement (any hematuria and/or proteinuria)
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and negative auto-antibody research, so there are no
markers which can predict a more severe course of the
disease [8, 10, 14, 15, 23, 25–27, 29–34, 36–39].
In the majority of the cases, the pulmonary symptoms
included cough, hemoptysis, epistaxis, dyspnea, tachyp-
nea, chest pain and shortness of breath through to acute
respiratory failure [8, 10, 14, 15, 23, 25–27, 30–35,
37–39]. However, pulmonary hemorrhage should be
considered also in HSP patients with no respiratory
symptoms or with common pulmonary manifestations.
Two of twenty-three patients had no respiratory
symptoms, but only radiological imaging findings sug-
gestive of DAH [29, 36]. So most but not all children
with pulmonary vasculitis have respiratory symptoms,
in some anemia or incidental radiological findings
bring it to attention.
The time between the onset of the disease and the oc-
currence of the respiratory symptoms ranged from 2
days to 3 weeks, with a mean of 12 days [8, 10, 14, 15,
23, 25–27, 30–35, 37, 38], except for 2 cases in which
the timing was not reported due to the absence of these
symptoms [29, 36].
The chest x-ray (CXR) was the first diagnostic step for
DAH, and in most cases showed a pattern of diffuse bi-
lateral pulmonary infiltrates.
In some cases, due to a misinterpretation of the CXR
findings, patients were treated with antibiotic therapy
due to a suspicion of a lobar pneumonia instead of DAH
[10, 27, 37]. For this reason, bronchoalveolar lavage
(BAL) should be performed to confirm diagnosis and
start treatment promptly. Five of twenty-three children
had BAL performed; the typical findings ranged from
the evidence of blood in the alveolar space in the acute
phase, to the presence of hemosiderin-laden macro-
phages in chronic hemorrhage [14, 27, 35, 37, 43].
Eighteen of twenty-three children (78%) had anemia
and decreased hematocrit values due to pulmonary
hemorrhage [8, 10, 14, 15, 23, 25–27, 30–33, 37, 38],
and nine (39%) needed red blood cell transfusion [10,
14, 15, 25, 31, 37].
Thirteen children (56%) required mechanical ventila-
tion, 12 of whom for respiratory distress, and remaining
patient for massive pulmonary hemorrhage [8, 10, 25,
26, 31–35, 37, 38]. The need for intubation was not re-
ported for two patients (8%) [23, 29].
The two patients without respiratory symptoms
achieved DAH resolution, in one case with oral prednis-
one therapy alone and in the other with oral prednisone
plus azathioprine [29, 36]. Four children with DAH died
despite treatment [8, 10, 23, 25]. In the remaining 17
surviving patients (73%), at the time of pulmonary in-
volvement, nine had required no therapy, three were be-
ing treated with oral prednisone and five with
intravenous pulse methylprednisolone (due to the
worsening of the kidney disease or to the massive lung
involvement on the computed tomography scan).
Of the nine patients who had not been prescribed any
medication, five of them needed mechanical ventilation
and all of them achieved resolution with pulse methyl-
prednisolone or with steroid treatment plus immuno-
suppressive therapy [10, 30–32, 36–38].
The three patients treated with oral prednisone did
not need intubation and all survived after receiving pulse
methylprednisolone with or without another immuno-
suppressive drug (cyclophosphamide) [14, 15, 27].
Of the five patients who were administered pulse
methylprednisolone, all of them needed mechanical ven-
tilation, three of them continued with pulse methylpred-
nisolone, and for the other two cyclophosphamide was
added to the intravenous steroid [8, 26, 33–35].
Before the onset of respiratory symptoms, 12 of the 17
children were not taking any medication or were on oral
prednisone (2 mg/kg/day), which could suggest that oral
steroid (and not intravenous steroid) seems not to pre-
vent pulmonary involvement. However, those patients
on oral steroid therapy did not need mechanical ventila-
tion. The absence of medication increased the risk of
acute respiratory failure, so steroid therapy was recom-
mended to avoid intubation and to reduce the mortality
rate [14, 15, 27].
No standard therapy was established for patients with
HSP with pulmonary involvement; however, the first
choice treatment was high-dose intravenous pulse meth-
ylprednisolone, with or without immunosuppressive
therapy. Oral steroid therapy was ineffective for the pre-
vention of lung involvement, considering that most pa-
tients were on oral steroids before the onset of DAH,
although it did reduce the risk of acute respiratory fail-
ure [14, 19, 36].
Four children died, the lung biopsy of three of them
were characterised by atelectasis, pulmonary edema with
intra-alveolar haemorrhage, interstitial fibrosis and dif-
fuse iron deposition [8, 10, 23, 25]. Among the 19 sur-
viving patients, 16 had a resolution after the first
episode, while three had a recurrent disease: the first re-
peated arthralgia and abdominal pains, the second a sin-
gle mild episode of purpura and the third multiple
reactivations [8, 10, 14, 15, 26, 27, 29–39].
Discussion and conclusion
HSP is one of the most common small-vessel vasculitis
in children. It is generally a self-limiting disease in which
the most feared complication is renal involvement.
Although rare, lung involvement in patients with HSP
could be asymptomatic and should be investigated in
order to diagnose potential lung involvement, due to a
disease progression to a more severe clinical presenta-
tion, such as DAH. TLCO could be performed early in
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patients with HSP to evaluate the presence of pulmonary
involvement even in the absence of symptoms, in order
to perform more investigations and to begin the appro-
priate supportive treatment immediately. Indeed the car-
bon monoxide diffusing capacity tests is lower in
children with HSP during the acute phase of the disease
and normal during resolution of the disease.
In patients with DAH, the most common clinical find-
ings are cough, hemoptysis, epistaxis, dyspnea, tachyp-
nea, chest pain and shortness of breath through to acute
respiratory failure that could require intubation and
mechanical ventilation. Limited data are available for the
prevention and treatment of lung involvement in HSP. It
was observed that oral corticosteroids are not sufficient
for the prevention of DAH, but they could reduce the
need for mechanical ventilation. No guidelines regarding
the treatment of DAH are so far available. Because of
the disease progression and the common associated
renal involvement, we suggest to treat every pulmonary
complication with intravenous methylprednisolone,
avoiding to wait an eventually life threatening complica-
tion as DAH. However, the best treatment for lung in-
volvement in HSP is still a matter of debate and needs
further researches.
Immunosuppressive treatment (azathioprine or cyclo-
phosphamide) is indicated in presence of respiratory
failure.
The limits of our article are that it is a narrative review
and it is based almost on case reports or small case
series. So, further multicentre studies on lung involve-
ment in HSP are essential in order to define a diagnostic
protocol, the best therapeutic strategies and their dur-
ation and the long-term outcomes.
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